LTTA Oncology Database and Study
When creating risk-based financial forecasts for investigational cancer drugs, there is a need for data about the time to approval from key events and the chance (likelihood) time to approval by certain times from key events. Blomquist & Associates has released the first study of the Time to Approval (TTA) and Likelihood Time to Approval (LTTA) from key events for investigational oncology drugs in clinical development using data extracted from the LTTA Oncology Database. Our study of the LTTA for investigational oncology agents meets this need.
Further, our study fills the gap between data for LOA (likelihood of approval) and for launch curve/peak sales. Analyzing data extracted from the LTTA Oncology Database can help improve the accuracy of risk-based forecasts for investors, as well as business executives, in the pharmaceutical and biotech industries. Key Findings Include:
|
|